PL3134123T3 - Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1 - Google Patents

Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1

Info

Publication number
PL3134123T3
PL3134123T3 PL15721044T PL15721044T PL3134123T3 PL 3134123 T3 PL3134123 T3 PL 3134123T3 PL 15721044 T PL15721044 T PL 15721044T PL 15721044 T PL15721044 T PL 15721044T PL 3134123 T3 PL3134123 T3 PL 3134123T3
Authority
PL
Poland
Prior art keywords
antibody
2rbeta
ctla
combination
selective agonists
Prior art date
Application number
PL15721044T
Other languages
English (en)
Polish (pl)
Inventor
Murali Krishna Addepalli
Deborah H. Charych
Seema Kantak
Steven Robert Lee
Original Assignee
Nektar Therapeutics (India) Pvt. Ltd.
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53055076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3134123(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics (India) Pvt. Ltd., Nektar Therapeutics filed Critical Nektar Therapeutics (India) Pvt. Ltd.
Publication of PL3134123T3 publication Critical patent/PL3134123T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL15721044T 2014-02-21 2015-02-20 Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1 PL3134123T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN499DE2014 2014-02-21
IN3087DE2014 2014-10-29
EP15721044.4A EP3134123B1 (en) 2014-02-21 2015-02-20 Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody
PCT/IN2015/000099 WO2015125159A1 (en) 2014-02-21 2015-02-20 Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody

Publications (1)

Publication Number Publication Date
PL3134123T3 true PL3134123T3 (pl) 2021-07-12

Family

ID=53055076

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15721044T PL3134123T3 (pl) 2014-02-21 2015-02-20 Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1

Country Status (21)

Country Link
US (3) US10010587B2 (enExample)
EP (2) EP3134123B1 (enExample)
JP (3) JP6963385B2 (enExample)
KR (1) KR102410090B1 (enExample)
CN (1) CN106132438B (enExample)
AU (3) AU2015220408B2 (enExample)
CA (1) CA2937660A1 (enExample)
CY (1) CY1124226T1 (enExample)
DK (1) DK3134123T3 (enExample)
ES (1) ES2872848T3 (enExample)
HR (1) HRP20210377T1 (enExample)
HU (1) HUE053982T2 (enExample)
IL (1) IL247320B (enExample)
LT (1) LT3134123T (enExample)
MX (2) MX385194B (enExample)
PL (1) PL3134123T3 (enExample)
PT (1) PT3134123T (enExample)
RS (1) RS61661B1 (enExample)
SI (1) SI3134123T1 (enExample)
SM (1) SMT202100191T1 (enExample)
WO (1) WO2015125159A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3211001B1 (en) 2010-12-22 2020-10-07 The Board of Trustees of the Leland Stanford Junior University Superagonists and antagonists of interleukin-2
FI3077041T3 (fi) 2013-12-05 2024-10-16 Rfemb Holdings Llc Syövän immunoterapia radiotaajuisella sähköisellä solukalvon hajotuksella (rf-emb)
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
PL3134123T3 (pl) * 2014-02-21 2021-07-12 Nektar Therapeutics (India) Pvt. Ltd. Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1
CA2946398A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US11141216B2 (en) 2015-01-30 2021-10-12 Immunsys, Inc. Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
RU2711380C2 (ru) 2015-07-16 2020-01-16 Байоксэл Терапьютикс, Инк. Новый подход к лечению рака с применением иммуномодуляции
US11262360B2 (en) 2015-10-02 2022-03-01 Julius-Maximilians-Universität Würzburg GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
CA3000211A1 (en) * 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
KR20180113976A (ko) 2015-11-20 2018-10-17 센화 바이오사이언시즈 인코포레이티드 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법
US11612426B2 (en) 2016-01-15 2023-03-28 Immunsys, Inc. Immunologic treatment of cancer
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
BR112019003248A2 (pt) * 2016-08-19 2019-10-01 Brooklyn Immunotherapeutics Llc usos de inibidores de pd-1/pd-l1 e/ou inibidores de ctla-4 com um biológico contendo múltiplos componentes citocínicos para o tratamento de câncer
MA46771A (fr) * 2016-11-10 2021-06-02 Univ Texas Méthode de traitement de tumeur immunothérapeutique
KR102619747B1 (ko) * 2017-01-10 2023-12-29 넥타르 테라퓨틱스 Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
EP3589303A4 (en) 2017-03-01 2020-11-25 Nektar Therapeutics Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
MA48862A (fr) * 2017-05-02 2020-04-01 Nektar Therapeutics Méthode de traitement de tumeur immunothérapeutique
BR112019024745B1 (pt) * 2017-05-25 2024-01-16 Institute For Basic Science Anticorpo anti-hil-2 ou fragmento de ligação a antígeno do mesmo,ácido nucleico, vetor recombinante, célula procariótica transformada, método para a produção de um anticorpo anti-hil-2 ou um fragmento do mesmo e complexo
CN111201035A (zh) 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
EP3668548A2 (en) * 2017-08-17 2020-06-24 Nektar Therapeutics Immunotherapeutic tumor treatment method
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
JP2021502344A (ja) * 2017-11-06 2021-01-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍を処置する方法
EP3706770A4 (en) * 2017-11-07 2021-10-27 Nektar Therapeutics IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF CANCER
US20200317784A1 (en) * 2017-11-13 2020-10-08 Bioxcel Therapeutics, Inc. Methods and compositions for treating cancer by modifying multiple arms of the immune system
EP3713592A4 (en) 2017-11-21 2022-01-12 The Board of Trustees of the Leland Stanford Junior University INTERLEUKIN-2 PARTIAL AGONISTS
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019168688A2 (en) 2018-02-15 2019-09-06 Senhwa Biosciences, Inc. Quinolone analogs and their salts, compositions, and method for their use
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
CA3093722A1 (en) * 2018-03-28 2019-10-03 Ascendis Pharma Oncology Division A/S Il-2 conjugates
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
KR20210020907A (ko) 2018-05-14 2021-02-24 웨어울프 세라퓨틱스, 인크. 활성화가능한 인터루킨 12 폴리펩타이드 및 이의 사용 방법
US20210355223A1 (en) 2018-11-05 2021-11-18 Pfizer Inc. Combinations for Treating Cancer
WO2020095183A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combination for treating cancer
KR20210092769A (ko) 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 항-nkg2a 항체 및 그의 용도
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
AU2020384375A1 (en) 2019-11-14 2022-05-26 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CA3162406A1 (en) 2020-01-10 2021-07-15 Vijaya Raghavan PATTABIRAMAN Modified il-2 polypeptides and uses thereof
US11491205B2 (en) 2020-01-14 2022-11-08 Synthekine, Inc. Biased IL2 muteins methods and compositions
CA3168738A1 (en) * 2020-05-26 2021-12-02 Matthew G. Fury Methods of treating cervical cancer by administering a pd-1 inhibitor
US12428461B2 (en) 2020-06-03 2025-09-30 Ascendis Pharma Oncology Division A/S Treating cancer with a conjugate comprising an IL-2 moiety
WO2022098954A1 (en) 2020-11-06 2022-05-12 Nektar Therapeutics Tlr agonist compounds and related cancer immunotherapy methods
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
SI4267105T1 (sl) 2020-12-28 2025-07-31 Bristol-Myers Squibb Company Sestave protiteles in načini njihove uporabe
EP4313154A4 (en) * 2021-03-29 2025-05-07 AJ Sciences (Yixing) Co., Ltd Protein-macromolecule conjugates and methods of use thereof
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
WO2022256534A1 (en) * 2021-06-03 2022-12-08 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
EP4366779A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Modified tnf-antibodies and uses thereof
CA3258064A1 (en) 2022-06-02 2023-12-07 Bristol Myers Squibb Co ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60006541D1 (de) * 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
CN101084012A (zh) * 2004-05-20 2007-12-05 津莫吉尼蒂克斯公司 使用il－21和单克隆抗体疗法治疗癌症的方法
JP4361545B2 (ja) * 2005-05-09 2009-11-11 小野薬品工業株式会社 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
HUE025208T2 (en) 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
AU2011325989C1 (en) 2010-11-12 2015-04-23 Endocyte, Inc. Methods of treating cancer
JP2014506116A (ja) * 2010-11-12 2014-03-13 ウェルズ ファーゴ バンク ナショナル アソシエイション Ｉｌ−２部分とポリマーとのコンジュゲート
CN103476943A (zh) * 2011-03-10 2013-12-25 普罗维克图斯药品公司 用于增强治疗癌症的局部和全身性免疫调节疗法的组合
PL3134123T3 (pl) * 2014-02-21 2021-07-12 Nektar Therapeutics (India) Pvt. Ltd. Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1

Also Published As

Publication number Publication date
WO2015125159A1 (en) 2015-08-27
CY1124226T1 (el) 2022-05-27
AU2015220408B2 (en) 2020-05-07
US20180344810A1 (en) 2018-12-06
CA2937660A1 (en) 2015-08-27
LT3134123T (lt) 2021-04-12
EP3834838A1 (en) 2021-06-16
DK3134123T3 (da) 2021-04-06
ES2872848T3 (es) 2021-11-02
HUE053982T2 (hu) 2021-08-30
JP2021073296A (ja) 2021-05-13
KR20160122748A (ko) 2016-10-24
CN106132438A (zh) 2016-11-16
IL247320A0 (en) 2016-09-29
RS61661B1 (sr) 2021-04-29
MX2021009926A (es) 2021-09-21
PT3134123T (pt) 2021-03-22
JP2017506264A (ja) 2017-03-02
HRP20210377T1 (hr) 2021-04-16
AU2015220408A1 (en) 2016-08-11
IL247320B (en) 2022-09-01
SMT202100191T1 (it) 2021-05-07
EP3134123A1 (en) 2017-03-01
US20170128539A1 (en) 2017-05-11
CN106132438B (zh) 2020-03-03
AU2020213296A1 (en) 2020-08-27
US10786552B2 (en) 2020-09-29
MX385194B (es) 2025-03-14
AU2022203550A1 (en) 2022-06-16
JP6963385B2 (ja) 2021-11-10
US10010587B2 (en) 2018-07-03
SI3134123T1 (sl) 2021-08-31
EP3134123B1 (en) 2021-02-17
MX2016010870A (es) 2016-10-26
KR102410090B1 (ko) 2022-06-16
JP2019077723A (ja) 2019-05-23
US20200368321A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
PL3134123T3 (pl) Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1
IL282403B1 (en) Antibodies against pd-1
IL267025A (en) Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
IL251963A0 (en) Anti-1-pd antibodies
HUS2500024I1 (hu) ANTI-PD-1 ellenanyagok
IL250415A0 (en) Antibodies against pd-l1
IL258214A (en) Antibodies - anti-pd-1 and preparations
SI3512547T1 (sl) Anti-PD-1 protitelesa
ZA201700832B (en) Anti-pd-l1 antibodies and diagnostic uses thereof
SG10201603721TA (en) Anti-CTLA-4 Antibodies
EP3176180A4 (en) Anti-pd-1 antibody and use thereof
SG11201705552QA (en) Anti-pd-l1 antibodies
IL248802A0 (en) Antibody formulation
HK40112828A (zh) 抗pd-l1抗体
HK40007701A (en) Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
GB201419080D0 (en) Anti-PD-1 antibodies
GB201419087D0 (en) Anti-PD-1 antibodies
TH1501007746A (th) แอนติ-pd-1 แอนติบอดี และการใช้งานของมัน
HK1239716A1 (en) Anti-pd-l1 antibodies